Thiopurines

Showing study: Azathioprine and 6-Mercaptopurine for the Prevention of Postoperative Recurrence in Crohn's Disease: A Meta-Analysis (Peyrin-Biroulet et al.)

Benefits

Risk

Overtime:
SHOW:
grid-1
grid-1

Benefit

Harm

Study overview

  • Figure shows absolute benefit/risk. This is calculated by assessing benefit/risk of study drug against control arms except where stated
  • Meta-analysis of four controlled trials, totalling 433 patients, comparing azathioprine (n=3) or (6-MP) (n=1) with control arms (placebo with or without antibiotic induction therapy or mesalamine)
  • As meta-analysis provides NNT data, these have been used in this visualization
 

Terms and conditions

By using this site you acknowledge that the content of this website is based on a review process of the ECCO Consensus Guidelines and primarily aims at facilitating their visualization.

Any treatment decisions are a matter for individual clinicians and may not be based primarily on the e-Guide content.

The European Crohn's and Colitis Organisation and/or any of its staff members and/or any website contributor may not be held liable for any information published in good faith on this website.

You agree that the use of this website is at your own risk and hereby waive any and all potential claims against European Crohn's and Colitis Organisation, and/or any of its staff members and/or any of the website contributors.